Department of Urology, University Hospital Frankfurt, Theodor- Stern Kai 7, 60590, Frankfurt am Main, Germany.
Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.
Cancer Causes Control. 2021 Jun;32(6):627-634. doi: 10.1007/s10552-021-01416-2. Epub 2021 Mar 22.
We assessed contemporary incidence rates and trends of primary urethral cancer.
We identified urethral cancer patients within Surveillance, Epidemiology and End Results registry (SEER, 2004-2016). Age-standardized incidence rates per 1,000,000 (ASR) were calculated. Log linear regression analyses were used to compute average annual percent change (AAPC).
From 2004 to 2016, 1907 patients with urethral cancer were diagnosed (ASR 1.69; AAPC: -0.98%, p = 0.3). ASR rates were higher in males than in females (2.70 vs. 0.55), respectively and did not change over the time (both p = 0.3). Highest incidence rates were recorded in respectively ≥75 (0.77), 55-74 (0.71) and ≤54 (0.19) years of age categories, in that order. African Americans exhibited highest incidence rate (3.33) followed by Caucasians (1.72), other race groups (1.57) and Hispanics (1.57), in that order. A significant decrease occurred over time in Hispanics, but not in other race groups. In African Americans, male and female sex-stratified incidence rates were higher than in any other race group. Urothelial histological subtype exhibited highest incidence rate (0.92), followed by squamous cell carcinoma (0.41), adenocarcinoma (0.29) and other histologies (0.20). In stage stratified analyses, TNM stage exhibited highest incidence rate. However, it decreased over time (-3.00%, p = 0.02) in favor of TNM stage (+ 2.11%, p = 0.02).
Urethral cancer is rare. Its incidence rates are highest in males, elderly patients, African Americans and in urothelial histological subtype. Most urethral cancer cases are TNM, but over time, the incidence of TNM decreased in favor of TNM.
评估原发性尿道癌的当代发病率和趋势。
我们在监测、流行病学和最终结果登记处（SEER，2004-2016 年）中确定了尿道癌患者。每 100 万人的年龄标准化发病率（ASR）进行计算。对数线性回归分析用于计算平均年百分变化（AAPC）。
2004 年至 2016 年，诊断出 1907 例尿道癌患者（ASR 为 1.69；AAPC：-0.98%，p=0.3）。男性的 ASR 率高于女性（分别为 2.70 比 0.55），且随时间变化无变化（两者均为 p=0.3）。年龄分别在≥75 岁（0.77）、55-74 岁（0.71）和≤54 岁（0.19）的发病率最高。非洲裔美国人的发病率最高（3.33），其次是白种人（1.72）、其他种族群体（1.57）和西班牙裔（1.57）。西班牙裔的发病率随着时间的推移而显著下降，但其他种族群体没有。在非洲裔美国人中，男性和女性的发病率均高于任何其他种族群体。尿路上皮组织学亚型的发病率最高（0.92），其次是鳞状细胞癌（0.41）、腺癌（0.29）和其他组织学类型（0.20）。在分期分层分析中，TNM 分期的发病率最高。然而，随着时间的推移，它呈下降趋势（-3.00%，p=0.02），有利于 TNM 分期（+2.11%，p=0.02）。
尿道癌罕见。其发病率在男性、老年患者、非洲裔美国人和尿路上皮组织学亚型中最高。大多数尿道癌病例为 TNM，但随着时间的推移，TNM 的发病率下降有利于 TNM。
